Human regulatory T cells (Tregs) pre-activated on dendritic cells acquire the ability to suppress even strongly stimulated effector T cells, and antibody blocking of MHC class II molecules on these activated Tregs abrogates that suppression (Peiser, Becht and Wanner, Allergy 2007). Eighteen years of follow-up literature has reproduced this HLA-class-II dependence but has not identified the molecular mechanism: the receptor on the effector T cell that engages Treg-surface MHC class II, whether the interaction is peptide-dependent, and whether MHC class II merely arranges the cell-cell contact or itself delivers the suppressive signal all remain unknown. The problem is to determine this mechanism.

Background

Regulatory T cells (Tregs) are CD4+ T lymphocytes (T cells carrying the CD4 co-receptor) that restrain other immune cells; in humans they are typically identified by high expression of CD25 (the interleukin-2 receptor alpha chain) and the transcription factor FoxP3, and they maintain peripheral self-tolerance. Unlike resting mouse Tregs, activated human T cells, including Tregs, express MHC class II molecules (in humans the HLA-DP, -DQ and -DR isotypes) — the peptide-presenting molecules otherwise characteristic of professional antigen-presenting cells. Peiser, Becht and Wanner (Allergy 2007) reported the following chain of observations: freshly isolated human Tregs were first co-cultured briefly with allogeneic (genetically unrelated, of the same species) monocyte-derived dendritic cells (moDCs — dendritic cells, the principal antigen-presenting cells of the immune system, here generated from blood monocytes), then the dendritic cells were removed so that the now-activated Tregs became physically accessible to effector T cells. These activated Tregs efficiently suppressed autologous (from the same donor) effector T cells whose proliferation was strongly driven by CD3/CD28 antibody-coated beads, i.e. by antibodies that directly trigger the T-cell receptor complex (CD3) and the co-stimulatory receptor CD28, a stimulus that bypasses antigen presentation. Blocking MHC class II on the activated Tregs with antibodies abrogated this suppression, implicating Treg-surface MHC class II itself in a direct Treg-to-effector-cell contact. A key prior result provides relevant background: Baecher-Allan, Wolf and Hafler (J Immunol 2006) showed that HLA-DR-expressing CD4+CD25high human Tregs constitute a functionally distinct, highly FoxP3-positive, contact-dependent suppressive subset. Related mechanistic candidates exist but all point the other way: Treg-surface LAG-3 (CD223, an inhibitory receptor) engaging MHC class II on dendritic cells, and CTLA-4 (cytotoxic T-lymphocyte antigen 4, an inhibitory receptor on Tregs) stripping peptide-MHC II from dendritic cells, concern MHC class II on antigen-presenting cells rather than on the Treg. Work on trogocytosis (transfer of membrane fragments, including peptide-loaded MHC class II, from antigen-presenting cells to T cells) shows that Tregs can carry and present acquired peptide-MHC class II complexes with regulatory consequences in mice, but this has not been connected to the human contact bridge. The authors of the 2007 study themselves cautioned that self-MHC molecules on activated Tregs may only arrange the contact to effector T cells rather than constitute the suppressive mechanism itself — a caution echoed by the most direct follow-up (Pacini et al., Eur J Immunol 2025), which lists three unresolved hypotheses: engagement of cytotoxicity, mere contact arrangement with a second suppressive mode acting thereafter, or a self-regulating interaction with LAG-3. How this MHC-class-II-dependent contact mechanism integrates with the better-characterized suppressive pathways of human Tregs (CTLA-4, interleukin-10, granzyme-mediated killing) is likewise undetermined.

Problem Statement

Determine the molecular mechanism by which MHC class II molecules on activated human regulatory T cells mediate contact-dependent suppression of effector T cells, as observed by Peiser et al. (Allergy 2007) and reproduced by Pacini et al. (Eur J Immunol 2025). Concretely: (i) identify the molecule or molecular pair on the effector T cell that engages MHC class II on the activated Treg — for example the effector-cell T cell receptor recognizing peptide-loaded self-MHC class II, a receptor such as LAG-3, or another counter-structure; (ii) establish whether MHC class II merely arranges the physical contact between the two cells while a second, still-unidentified suppressive effector mechanism acts, or whether engagement of Treg-surface MHC class II itself delivers the suppressive signal; and (iii) determine whether the engagement of Treg-surface MHC class II by the effector-cell counter-structure is peptide-dependent or instead relies on peptide-independent recognition of self-MHC class II. These three parts are jointly required to resolve the task — no single part alone resolves it — and the task counts as resolved by a mechanistic account of the interaction, whether experimentally demonstrated or advanced as a well-argued, evidence-based hypothesis, that identifies the effector-cell counter-structure, settles whether Treg-surface MHC class II merely arranges contact or itself delivers the signal, and determines whether the engagement is peptide-dependent.

References

  1. Peiser M, Becht A, Wanner R. Antibody blocking of MHC II on human activated regulatory T cells abrogates their suppressive potential. Allergy 2007;62(7):773-780. DOI 10.1111/j.1398-9995.2007.01339.x. https://doi.org/10.1111/j.1398-9995.2007.01339.x
  2. Baecher-Allan C, Wolf E, Hafler DA. MHC class II expression identifies functionally distinct human regulatory T cells. J Immunol 2006;176(8):4622-4631. DOI 10.4049/jimmunol.176.8.4622. https://doi.org/10.4049/jimmunol.176.8.4622
  3. Schmidt A, Oberle N, Krammer PH. Molecular mechanisms of Treg-mediated T cell suppression. Front Immunol 2012;3:51. DOI 10.3389/fimmu.2012.00051. https://doi.org/10.3389/fimmu.2012.00051
  4. Kisielewicz A, Schaier M, Schmitt E, Hug F, Haensch GM, Meuer S, Zeier M, Sohn C, Steinborn A. A distinct subset of HLA-DR+-regulatory T cells is involved in the induction of preterm labor during pregnancy and in the induction of organ rejection after transplantation. Clin Immunol 2010;137(2):209-220. DOI 10.1016/j.clim.2010.07.008. https://doi.org/10.1016/j.clim.2010.07.008
  5. Zhou G, Ding ZC, Fu J, Levitsky HI. Presentation of acquired peptide-MHC class II ligands by CD4+ regulatory T cells or helper cells differentially regulates antigen-specific CD4+ T cell response. J Immunol 2011;186(4):2148-2155. DOI 10.4049/jimmunol.1002917. https://doi.org/10.4049/jimmunol.1002917
  6. Bianchi J, Vieira AIS, Ligeiro D, Azevedo RI, Lacerda JF. Suppression by Allogeneic-Specific Regulatory T Cells Is Dependent on the Degree of HLA Compatibility. Immunohorizons 2021;5(5):307-321. DOI 10.4049/immunohorizons.2100021. https://doi.org/10.4049/immunohorizons.2100021
  7. Ma X, Cao L, Raneri M, Wang H, Cao Q, Zhao Y, Bediaga NG, Naselli G, Harrison LC, Hawthorne WJ, Hu M, Yi S, O'Connell PJ. Human HLA-DR+CD27+ regulatory T cells show enhanced antigen-specific suppressive function. JCI Insight 2023;8(23):e162978. DOI 10.1172/jci.insight.162978. https://doi.org/10.1172/jci.insight.162978
  8. Gootjes C, Zwaginga JJ, Roep BO, Nikolic T. Defining Human Regulatory T Cells beyond FOXP3: The Need to Combine Phenotype with Function. Cells 2024;13(11):941. DOI 10.3390/cells13110941. https://doi.org/10.3390/cells13110941
  9. Pacini CP, Azevedo RI, Ramalhete L, Lainé HAJ, Soares MVD, Lacerda JF. Selection and Characterisation of Minor Histocompatibility Antigen-Specific Regulatory T Cells in Fully HLA-Matched Setting for GVHD Therapy. Eur J Immunol 2025;55(12):e70096. DOI 10.1002/eji.70096. https://doi.org/10.1002/eji.70096
  10. Zhang J, Liao B, Wang X, Liu W. Immunomodulatory Role and Therapeutic Potential of HLA-DR+ Regulatory T Cells in Systemic Lupus Erythematosus. Immunol Invest 2025;54(5):677-694. DOI 10.1080/08820139.2025.2475816. https://doi.org/10.1080/08820139.2025.2475816
  11. Liang B, Workman C, Lee J, Chew C, Dale BM, Colonna L, Flores M, Li N, Schweighoffer E, Greenberg S, Tybulewicz V, Vignali D, Clynes R. Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II. J Immunol 2008;180(9):5916-5926. DOI 10.4049/jimmunol.180.9.5916. https://doi.org/10.4049/jimmunol.180.9.5916